UNIVERSITY COLLEGE Sample Clauses

UNIVERSITY COLLEGE. CARDIFF CONSULTANTS LTD a company incorporated under the laws of England and Wales (company number 1477909) whose registered office is at 00-00 Xxxxxxx Xxxx, Xxxxxxx, Xxxxxx Xxxxxxx, XX00 0XX (“UC3”); and
Sample 1Sample 2See All (5)
AutoNDA by SimpleDocs
UNIVERSITY COLLEGE a. Subject to Article B.22.4.c, full credit shall be granted for teaching experience gained as a member of the faculty of an accredited university or college in Canada, the United States and in countries currently or previously members of the British Commonwealth, where the teaching load is nine (9) or more class contact hours per week.
Sample 1Sample 2Sample 3See All (4)
UNIVERSITY COLLEGE. A higher education institution that the Tenant is attending for the purpose of completing undergraduate or post-graduate qualification.
Sample 1Sample 2
UNIVERSITY COLLEGE. American Campus (PVAMU IV) Ltd. (Ground Lessee Entity) * 99% American Campus Communities, L.L.C.; 1% SPE (PVAMU IV), L.L.C. SPE (PVAMU IV), L.L.C. * 100% American Campus Communities, L.L.C. Entity RSVP Ownership Interests in Entity UNIVERSITY VILLAGE AT LAREDO American Campus (LAREDO) Ltd. (Ground Lessee Entity) * 99% American Campus Communities, L.L.C.; 1% SPE (Laredo), L.L.C. SPE (LAREDO), L.L.C. * 100% American Campus Communities, L.L.C. CULLEN OAKS American Campus (U of H), Ltd. (Ground Lessee Entity) * 99% American Campus Communities, L.L.C.; 1% American Campus (U of H) GP, LLC American Campus (U of H) GP, LLC* 100% American Campus Communities, L.L.C. SHP ENTITIES RIVER CLUB SHP-Riverclub LLC (Property Owning Entity) 1% RFG-CMP Riverclub LLC RFG-CMP Riverclub LLC 100% RFG Capital Management Partners, LP RIVER WALK SHP-Riverwalk LLC (Property Owning Entity) 1% RFG-CMP Riverwalk LLC RFG-CMP Riverwalk LLC 100% RFG Capital Management Partners, LP VILLAGE AT ALAFAYA CLUB SHP-The Village at Alafaya Club LLC (Property Owning Entity) 1% RFG-CMP The Village at Alafaya Club, LLC Entity RSVP Ownership Interests in Entity RFG-CMP The Village at Alafaya Club, LLC 100% RFG Capital Management Partners, LP
Sample 1
UNIVERSITY COLLEGE. University College of the Fraser Valley; UCFV Board; Board; the Employer.
Sample 1
UNIVERSITY COLLEGE. Property. All personal property (excluding vehicle(s) provided through the Vandal Wheels program), material, and articles of information, including, without limitation, keys, credit cards, personnel records, recruiting records, team information, films, statistics or any other personal property, material, or data, furnished to Coach by the University (College) or developed by Coach on behalf of the University (College) or at the University (College)’sUniversity’s direction or for the University (College)’sUniversity’s use or otherwise in connection with Coach’s employment hereunder are and shall remain the sole property of the University (College).. Within twenty-four (24) hours of the expiration of the term of this agreementAgreement or its earlier termination as provided herein, Coach shall immediately cause any such personal property, materials, and articles of information in Coach’s possession or control to be delivered to the Director.
Sample 1
UNIVERSITY COLLEGE. _______________University/College verifies the above named student is an Academic Challenge Scholarship recipient and is eligible to provide tutoring services as described in Act 341. University/College Official __________________________ Date______________ School/District _________________School/District agrees to allow the above named student to provide tutoring services after completion of required district training. The district will assure the tutor is supervised at all times by a district employee. Documentation of tutoring hours must be maintained by the student and verified by a school official. School Official _____________________________ Date_____________
Sample 1
AutoNDA by SimpleDocs

Related to UNIVERSITY COLLEGE

  • Technology Transfer Subject to the terms of the Development Supply Agreement, as soon as reasonably practicable, but in no event later than the fifth (5th) anniversary of the Effective Date, Alnylam shall initiate a technology transfer to MedCo, or to its Third Party manufacturer(s) of Licensed Product, selected by MedCo and reasonably acceptable to Alnylam, of Alnylam Know-How that is reasonably necessary or useful for the Manufacture of the Licensed Product, and shall make available its personnel on a reasonable basis to consult with MedCo or such Third Party manufacturer(s) with respect thereto, all at MedCo’s expense, including the Costs reasonably incurred by Alnylam in connection with such technology transfer activities. MedCo shall reimburse Alnylam such Costs incurred with respect to such Manufacturing technology transfer within [***] days after receipt of an invoice therefor. Alnylam and its Affiliates shall keep complete and accurate records in sufficient detail to enable the payments payable hereunder to be determined. Alnylam shall not be required to perform technology transfer to more than one Third Party manufacturer for each stage of the Licensed Product supply chain (i.e., Bulk Drug Substance, Bulk Drug Product and Finished Product). Promptly after MedCo’s written request, Alnylam shall use Commercially Reasonable Efforts to assign to MedCo any manufacturing agreement between Alnylam and a Third Party that is solely related to the manufacture of Licensed Products. Such assignment shall be subject to the terms and conditions of such agreement, including any required consents of such Third Party and MedCo’s written agreement to assume all the obligations of Alnylam under such agreement to be undertaken after such assignment, but Alnylam shall remain solely responsible for its obligations under such agreement arising prior to such assignment. Except as provided in the immediately preceding sentence, MedCo shall be solely responsible for contracting with such Third Party manufacturer (and any other Third Party manufacture to whom Alnylam has initiated technology transfer as set forth in this Section 5.3) for the supply of such Licensed Product and Alnylam shall have no obligations under such agreement between MedCo and such Third Party manufacturer. Alnylam shall use Commercially Reasonable Efforts to obtain any such consent in a form reasonably acceptable to MedCo.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Research Funding Genocea shall pay to Isconova in total [* * *] payable as follows: (i) $[* * *] in equal monthly installments for each remaining month in 2009 following the Effective Date and (ii) $[* * *] in equal monthly installments during the period from January 1, 2010 until March 31, 2012. The Research Funding shall be used solely for the performance of activities under the Research and Phase 1 Supply Plan and the Development and Scale-Up Plan and, for the avoidance of doubt, solely to fund Development and research activities for human (and not veterinary) applications in accordance with such Research and Phase 1 Supply Plan and Development and Scale-Up Plan. Notwithstanding anything to the contrary above, the Parties agree that this restriction shall only apply to the allocation and use of the Research Funding as such, and shall not be construed as limiting or affecting the ownership of any Isconova Technology and Joint Technology created, conceived, reduced to practice or Invented hereunder. Isconova’s ownership and/or rights to the Isconova Technology and Joint Technology shall exclusively be governed by the provisions in Section 3.3. and Isconova’s use of the Isconova Technology and Joint Technology shall be subject only to the licenses granted to Genocea in Sections 3.1.1 through 3.1.3. Isconova shall during the Research Term allocate not less than two (2) dedicated FTEs for Isconova’s research work for Genocea hereunder and each such dedicated FTE shall be paid through Research Funding. During the Research Term, Isconova shall, within fifteen (15) days after the end of each month, deliver to Genocea a report setting forth the number of Isconova FTEs that worked on activities under the Development and Scale-Up Plan and the Research and Phase 1 Supply Plan, as well as other costs and expenses of Isconova evidencing recourses spent on Isconova’s research work hereunder. Researching Funding THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. payments shall be made within fifteen (15) days after the end of each calendar month.

  • Principal Investigator The research will be under the direction of (“Principal Investigator”). If, for any reason, he/she is unable to continue to serve as Principal Investigator and a successor acceptable to both UHD and Sponsor is not available, this Agreement shall be terminated as provided in Section 7.

  • Business Development Company Buyer is a business development company as defined in Section 202(a)(22) of the Investment Advisors Act of 1940.

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner.

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • Research License Each Collaborator shall allow the other Collaborator to practice any of its Non- Subject Inventions for the purpose of performing the Cooperative Work. No license, express or implied, for commercial application(s) is granted to either Collaborator in Non-Subject Inventions by performing the Cooperative Work. For commercial application(s) of Non-Subject Inventions, a license must be obtained from the owner.

Time is Money Join Law Insider Premium to draft better contracts faster.